Search Results - Mark R. Litzow

Refine Results
  1. 1
    No free rides: management of toxicities of novel immunotherapies in ALL, including financial

    No free rides: management of toxicities of novel immunotherapies in ALL, including financial by Tania Jain, Mark R. Litzow

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia

    Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia by Tania Jain, Mark R. Litzow

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    No free rides: management of toxicities of novel immunotherapies in ALL, including financial

    No free rides: management of toxicities of novel immunotherapies in ALL, including financial by Tania Jain, Mark R. Litzow

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    How I treat T-cell acute lymphoblastic leukemia in adults

    How I treat T-cell acute lymphoblastic leukemia in adults by Mark R. Litzow, Adolfo A. Ferrando

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

    Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis by Ayalew Tefferi, Mark R. Litzow, Animesh Pardanani

    Published 2011
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  6. 6
    Hematologic manifestations of celiac disease

    Hematologic manifestations of celiac disease by Þorvarður R. Hálfdánarson, Mark R. Litzow, Joseph A. Murray

    Published 2006
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Bacteremia Due to Viridans Group Streptococci with Diminished Susceptibility to Levofloxacin among Neutropenic Patients Receiving Levofloxacin Prophylaxis

    Bacteremia Due to Viridans Group Streptococci with Diminished Susceptibility to Levofloxacin among Neutropenic Patients Receiving Levofloxacin Prophylaxis by Raymund R. Razonable, Mark R. Litzow, Yasmin Khaliq, Kerryl E. Piper, Mark S. Rouse, Robin Patel

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A systematic review of religious beliefs about major end-of-life issues in the five major world religions

    A systematic review of religious beliefs about major end-of-life issues in the five major world religions by Rajshekhar Chakraborty, Areej El‐Jawahri, Mark R. Litzow, Karen L. Syrjala, Aric Parnes, Shahrukh K. Hashmi

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease

    Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease by Gaurav Goyal, Mithun Vinod Shah, Timothy G. Call, Mark R. Litzow, William J. Hogan, Ronald S. Go

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set

    Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set by Gaurav Goyal, Adam C. Bartley, Mrinal M. Patnaik, Mark R. Litzow, Aref Al‐Kali, Ronald S. Go

    Published 2017
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  11. 11
    A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis

    A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis by Na Shen, Fei Yan, Jiuxia Pang, Lai‐Chu Wu, Aref Al‐Kali, Mark R. Litzow, Shujun Liu

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Pulmonary Complications in Adult Blood and Marrow Transplant Recipients

    Pulmonary Complications in Adult Blood and Marrow Transplant Recipients by Sunita Sharma, Hassan F. Nadrous, Steve G. Peters, Ayalew Tefferi, Mark R. Litzow, Marie-Christine Aubry, Bekele Afessa

    Published 2005
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival

    Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival by Michelle A. Elliott, Mark R. Litzow, Louis Letendre, Robert Christian Wolf, Curtis A. Hanson, Ayalew Tefferi, Martin S. Tallman

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

    Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhib... by Naseema Gangat, Kebede H. Begna, Aref Al‐Kali, William J. Hogan, Mark R. Litzow, Animesh Pardanani, Ayalew Tefferi

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis

    Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis by Jacob M. Rowe, Haesook T. Kim, Peter A. Cassileth, Hillard M. Lazarus, Mark R. Litzow, Peter H. Wiernik, Martin S. Tallman

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

    A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors by Fei Yan, Aref Al‐Kali, Zijie Zhang, Jun Liu, Jiuxia Pang, Na Zhao, Chuan He, Mark R. Litzow, Shujun Liu

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole

    The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole by Jason N. Barreto, Cassidy Beach, Robert Christian Wolf, Julianna A. Merten, Pritish K. Tosh, John Wilson, William J. Hogan, Mark R. Litzow

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis

    Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A sys... by Luis Enrique Colunga‐Lozano, Fernando Kenji Nampo, Arnav Agarwal, Pinkal Desai, Mark R. Litzow, Mikkael A. Sekeres, Gordon Guyatt, Romina Brignardello‐Petersen

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  19. 19
    Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis

    Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis by Shaji Kumar, David Dingli, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Francis K. Buadi, S. Vincent Rajkumar, Mark R. Litzow, Morie A. Gertz

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

    Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903 by Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Mark R. Litzow, Elisabeth Paietta, Jacob M. Rowe, Ayalew Tefferi, Martin S. Tallman

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: